Senti Biosciences, Inc. (SNTI) is a Biotechnology company in the Healthcare sector, currently trading at $0.94. It has a SharesGrow Score of 34/100, indicating a weak investment profile with 2 out of 7 criteria passed.
Analyst consensus target is SNTI = $6 (+541.6% upside).
Valuation: SNTI trades at a trailing Price-to-Earnings (P/E) of -0.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.02.
Financials: revenue is $22,000, -70.1%/yr average growth. Net income is $61M (loss), growing at -10.9%/yr. Net profit margin is -279263.6% (negative). Gross margin is -16431.8% (-16440.3 pp trend).
Balance sheet: total debt is $29M against $6M equity (Debt-to-Equity (D/E) ratio 5.17, leveraged). Current ratio is 1.67 (strong liquidity). Debt-to-assets is 56.4%. Total assets: $51M.
Analyst outlook: 2 / 4 analysts rate SNTI as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 0/100 (Fail), Future 64/100 (Pass), Income 10/100 (Fail).
